Exclusive Summary

• - Originator patents for thymalfasin (Thymosin α1) have widely expired; 1.6 mg injection generics can enter most markets without core IP barriers.
• - Large unmet need in immune-modulating adjunct therapy across HBV (~254M), HCV (~50M), and sepsis (~49M cases/year) globally.
• - Not on the WHO Essential Medicines List; used mainly as an adjunct, with mentions in national guidelines/consensus (e.g., China) and mature real-world use.
• - Competition is originator-led in many countries with generics concentrated in China/Korea/parts of ASEAN/MENA; this product outperforms originator in Korea, proving market competitiveness.
• - Proven MFDS registration and long-term export to Korea, stable quality, and typical 30–60% price savings versus originator support fast distribution partnerships.

Asset Materials

Contact Us for Full Materials